VEGFA and neoplasm: In the clinical context, VEGF inhibitors—such as the monoclonal antibody Bevanzizumab—could be applied simultaneously with plasma treatment to tackle tumor growth by anti-angiogenic and pro-apoptotic therapies, simultaneously.